Cambio - Excellence in Molecular Biology

In vitro Transcription

In vitro Transcription: In Vitro Transcription

RiboGuard™ RNase Inhibitor

RiboGuard™ RNase Inhibitor

BioSearch Tech (Lucigen/Epicentre)

Catalogue No.DescriptionPack SizePriceQty
E0126-40D4RiboGuard™ RNase Inhibitor, 1.25 mL at 40 U/µL, 50,000 U1.25ml POA Quantity Add to Order
RG90910KRiboGuard™ RNase Inhibitor 10kU £296.00 Quantity Add to Order
RG90925RiboGuard™ RNase Inhibitor 2.5kU £119.00 Quantity Add to Order

Description

RiboGuard™ RNase Inhibitor is the best defense against common RNases, including RNase A, RNase B, and RNase C. This recombinant RNase inhibitor protein provides reliable protection of valuable RNA samples by binding strongly to RNases in a 1:1 ratio. Advanced purification protocols and extensive quality control tests ensure RiboGuard RNase Inhibitor is free of unwanted contaminants that can plague other commercially available preparations of RNase inhibitors.

Benefits

  • A potent affinity for RNases (Ki >10-14 M) ensures rapid inhibition even when trace amounts of RNase are present.
  • Free of detectable RNase or DNase activity, and mammalian DNA.
  • Does not interfere with enzymes commonly used to prepare or analyze RNA.
  • Less sensitive to oxidation than traditional RNase inhibitors.

Unit Definition: One unit of RiboGuard RNase Inhibitor results in 50% inhibition of 5 ng of RNase A. Activity is measured by the inhibition of hydrolysis of 2,3´-cyclic monophosphate by RNase A.

Storage Buffer: 50% glycerol solution containing 50 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 100 mM NaCl, and 10 mM DTT.

Quality Control: RiboGuard RNase Inhibitor is free of detectable DNA exo- and endonuclease, and RNase activities.

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

Protocols

protocol

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

References

  1. Chen, Y.-C., et al. (2010) Evolution of eukaryal tRNA-guanine transglycosylase: insight gained from the heterocyclic substrate recognition by the wild-type and mutant human and Escherichia coli tRNA-guanine transglycosylases. Nucleic Acids Res  , gkq1188.
  2. Bhatt, S., et al. (2009) The RNA binding protein CsrA is a pleiotropic regulator of the LEE pathogenicity island of enteropathogenic Escherichia coli. Infect Immun  , IAI.00418-09.

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

Applications & Benefits

  • Effective inhibition of the degradation of RNA by eukaryotic RNases in a variety of applications, including cDNA synthesis, RT-PCR, and in vitro transcription and translation.

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

Related products

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200